Phase 2 RCT in 129 patients with advanced pancreatic cancer: first-line SLOG was not superior to modified FOLFIRINOX for median PFS (7.5 vs 6.5 months; p=0.88), with less grade 3/4 neutropenia (15.4% vs 53.1%) but more grade 3/4 non-haematological toxicity.
RCTn = 129
Chiang et al. SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217)